Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs

Inclusion Criteria Patients may be eligible for this study if they: * Are HIV-positive. * Have a plasma viral load (level of HIV in the blood) of 10,000 copies/ml or more. * Have a CD4 count of 50 cells/mm3 or more. * Have a negative pregnancy test. * Agree to use 2 forms of barrier birth control while on the study and for 30 days afterwards. * Are 18 to 65 years old. Exclusion Criteria Patients will not be eligible for this study if they: * Have had treatment with any of the following types of anti-HIV drugs: nucleoside reverse transcriptase inhibitors, nucleotide reverse transcriptase inhibitors (e.g., adefovir dipivoxil or TDF), protease inhibitors, or nonnucleoside reverse transcriptase inhibitors. * Have received a vaccination within 30 days before study entry. * Have had a new AIDS-defining illness diagnosed within 30 days before study entry. * Are taking any of the following: drugs that may cause kidney problems, including aminoglycoside antibiotics, cidofovir, cisplatin, foscarnet, intravenous (IV) amphotericin B, IV vancomycin, oral and IV ganciclovir, and valganciclovir; probenecid; chemotherapy; steroid drugs; interleukin-2; or investigational drugs. * Are pregnant or breast-feeding. * Have difficulty taking, absorbing, or tolerating drugs by mouth, as may be shown by long-term nausea or vomiting. * Abuse alcohol or drugs. * Have cancer other than Kaposi's sarcoma or basal cell carcinoma. * Have other infections that need injectable antibiotics within 15 days before study entry. * Have had kidney or bone disease. * Have any medical conditions or past treatments that the study investigator believes would make the patient unsuitable for the study.